By Daniella Parra
Vaxxinity, Inc. (Nasdaq: VAXX) announced positive Phase 1 clinical trial results for their investigational immunotherapeutic, UB-312, in Parkinson’s disease patients.
The data showed that the antibodies effectively engage with aggregated alpha-synuclein, a toxic protein associated with PD, in the cerebrospinal fluid, the company said in a statement.
“This is a major milestone for Vaxxinity in our quest to help Parkinson’s patients,” said Mei Mei Hu, CEO of Vaxxinity. “Our candidate has shown target engagement of the toxic species of alpha-synuclein in patients, demonstrating not only proof of our technology platform, but also proof of the mechanism of our vaccine-derived antibodies specifically engaging with the toxic target in vivo.”